findmyKOL
Clinical trialNCT00896610TerminatedObservational

Natural History of Autoimmune Diabetes and Its Complications

SponsorNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Enrollment356Diabetes Mellitus Type 1Diabetes Mellitus Type 2
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

Background: * Diabetes is a disease defined by abnormally high blood sugar (glucose) levels. Glucose is an essential source of energy for the body s cells, but insulin is required to move the glucose into the cells. Insulin is a hormone produced by the pancreas that allows glucose to enter cells. * In diabetes, the body is unable to supply enough insulin to meet its demands. The problem may be a low supply of insulin or a high demand for insulin. Someone who has been diagnosed with diabetes has lost much of their insulin-producing capacity. Clinical studies have shown that good control of blood sugar is essential to prevent diabetes complications like damage to the eyes, kidneys, nerves, and blood vessels. Objectives: * To establish a relationship with several individuals with diabetes caused by the immune system attacking the body s insulin-producing cells in order to: * Explore why the immune system attacks insulin-producing cells. * Understand why some individuals develop diabetes-related complications and others do not. * Develop therapies to improve how patients can control their blood sugar levels. * Continue to follow subjects who have completed or are considering other NIH diabetes-related studies. * To develop improved tests for determining an individual s risk for developing diabetes and/or to accurately diagnose the exact type of diabetes. Eligibility: * Individuals who have been diagnosed with or are at risk for developing diabetes. Design: * Standard physical examination and clinical tests to determine if the patient has diabetes or to confirm a particular type of diabetes: * None of the treatment in this study is experimental. * Patients will receive a separate consent form for any special tests needed to learn more about their particular type of diabetes. * Patients may be asked to provide additional urine and blood samples for use in laboratory research about diabetes. * Researchers may offer medical treatment advice for diabetes, or explain how to improve patients diabetes management skills.

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

  • Ranganath Muniyappa, M.D.

    National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

    Principal Investigator

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • National Institutes of Health Clinical Center, 9000 Rockville Pike

    Bethesda, Maryland, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study. It may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
13 May 2009
Primary completion
30 Sept 2020
Completion
30 Sept 2020
Last update posted
8 Oct 2020
Registered enrollment
356
Registry id
NCT00896610

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.